Alendronate sodium and vitamin D in postmenopausal osteoporosis

Radominski SC, Bernardo W, Paula AP, Albergaria B, Moreira C, Fernandes CE, et al. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós-‐menopausa. Rev Bras Reumatol. 2017;57:452-66. https://doi.org/10.1016/j.rbre.2017.07.001

Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatmentof osteoporosis. Osteoporos Int. 2014;25:2359. https://doi.org/10.1007/s00198-014-2794-2

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285:785-95. https://doi.org/10.1001/jama.285.6.785

Lazaretti-Castro M, Eis SR, Marques Neto JF. A prevenção da osteoporose levada a sério: uma necessidade nacional. Arq Bras Endrocrinol Metab. 2008;52(4):712-3. https://doi.org/10.1590/S0004-27302008000400020

Mabey T, Honsawek S. Role of Vitamin D in osteoarthritis: molecular, cellular, and clinical perspectives. Int J Endocrinol. 2015;2015:1-14. https://doi.org/10.1155/2015/383918

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81. https://doi.org/10.1056/NEJMra070553

Narula K, Tauseef M, Ahmad I, Agarwal K, Ashok A, Anjana A. Vitamin D deficiency among postmenopausal women with osteoporosis. J Clin Diagn Res. 2013;7:336-8. https://doi.org/10.7860/JCDR/2013/5022.2761

Sahota O. Osteoporosis and the role of vitamin D and calcium-vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency. Age Ageing. 2000;29:301-4. https://doi.org/10.1093/ageing/29.4.301

Rosen CJ. The Epidemiology and pathogenesis of osteoporosis [Updated 2014 Jan 10]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext South Dartmouth (MA): MDText com, Inc. 2014; 2000: Available from: https://www.ncbi.nlm.nih.gov/books/NBK279134.

Agnusdei D, Crepaldi G, Isaia G, et al. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int. 1997;61(2):142-147. https://doi.org/10.1007/s002239900312

Kocijan R, Klaushofer K, Misof BM. Osteoporosis therapeutics 2020, Berlin, Heidelberg: Springer Berlin Heidelberg; 2020.

Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362(19):1761-71. https://doi.org/10.1056/NEJMe1003064

Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007;40(5): 1238-43. https://doi.org/10.1016/j.bone.2007.01.016

Higgins JP, Thomas J, Chandler J et al., editors. Cochrane handbook for systematic reviews of interventions. Chichester (UK): John Wiley & Sons; 2019.

Roux C, Binkley N, Boonen S, et al. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 2014;94(2):153-7. https://doi.org/10.1007/s00223-013-9763-1

Kim KJ, Min YK, Koh JM, et al. Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in korean osteoporotic women: 16-week randomized trial. Yonsei Med J. 2014;55(3):715-24. https://doi.org/10.3349/ymj.2014.55.3.715

Olmos JM, Hernández JL, Llorca J, et al. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate. J Clin Endocrinol Metab. 2012;97(12):4491–7. https://doi.org/10.1210/jc.2012-2999

Orimo H, Nakamura T, Fukunaga M, et al. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the japanese osteoporosis intervention trial (JOINT) - 02. Curr Med Res Opin. 2011;27(6):1273-84. https://doi.org/10.1185/03007995.2011.580341

Binkley N, Ringe JD, Reed JI, Ljunggren O, Holick MF, Minne HW, Liu M, Lamotta A, West JA, Santora AC. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. Bone. 2009;44(4):639-47. https://doi.org/10.1016/j.bone.2008.05.002

Recker R, Lips P, Felsenberg D, et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin. 2006;22(9):1745-55. https://doi.org/10.1185/030079906x120913

Mata PR, Martins PA, Brito LG, Ramos MMP, Santos Junior, MC. Tratamento farmacológico para a osteoporose. Geriatrics, Gerontology and Aging. 2012;6(4):422–31.

Benjamin B, Benjamin MA, Swe M, Sugathan S. Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis. Osteoporosis and Sarcopenia. 2016;2:77-81. https://doi.org/10.1016/j.afos.2016.03.003

Drieling RL, LaCroix AZ, Beresford SAA, Boudreau DM, Kooperberg C, Chlebowski RT, et al. Long-Term oral bisphosphonate therapy and fractures in older women: the women’s health initiative. J Am Geriatr Soc. 2017;65:1924-31. https://doi.org/10.1111/jgs.14911

Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. JMCP. 2009;15:728-40. https://doi.org/10.18553/jmcp.2009.15.9.728

Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, et al. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE USTM. Osteoporos Int. 2012;23:733-41. https://doi.org/10.1007/s00198-011-1620-3

Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the international society for clinical densitometry. J Clin Densitom. 2004;7:1-6. https://doi.org/10.1385/JCD:7:1:1

Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. The Lancet Diabetes & Endocrinology. 2017;5:908-23. https://doi.org/10.1016/S2213-8587(17)30184-5

Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 2001;38(6):608-623. https://doi.org/10.1258/0004563011901037

Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocaña A, Bisello A, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res. 2005;20:1792-1803. https://doi.org/10.1359/JBMR.050602

Cândido F, Bressan J. Vitamin D: Link between Osteoporosis, obesity, and diabetes? IJMS. 2014;15:6569-91. https://doi.org/0.3390/ijms15046569

Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257. https://doi.org/10.1001/jama.293.18.2257

留言 (0)

沒有登入
gif